2017. Adalimumab Efficacy in Hidradenitis Suppurativa Patients is Sustained at Least Three Years with Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER). SKIN The Journal of Cutaneous Medicine. 1, 3.1 (Oct. 2017), s128. DOI:https://doi.org/10.25251/skin.1.supp.127.